|
ES2251677T3
(es)
|
2002-01-22 |
2006-05-01 |
Warner-Lambert Company Llc |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
|
|
WO2005094830A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
US8247408B2
(en)
*
|
2005-10-07 |
2012-08-21 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
|
|
BRPI0617159B8
(pt)
*
|
2005-10-07 |
2021-05-25 |
Exelixis Inc |
compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
|
|
RU2009108006A
(ru)
*
|
2006-09-08 |
2010-10-20 |
Пфайзер Продактс Инк. (Us) |
Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
|
|
WO2008032162A1
(en)
|
2006-09-15 |
2008-03-20 |
Pfizer Products Inc. |
Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
EP2109450A2
(de)
*
|
2006-12-14 |
2009-10-21 |
Panacea Pharmaceuticals, Inc. |
Verfahren zur neuroprotektion durch cyclin-abhängige kinasehemmung
|
|
US9259399B2
(en)
*
|
2007-11-07 |
2016-02-16 |
Cornell University |
Targeting CDK4 and CDK6 in cancer therapy
|
|
BRPI0821209A2
(pt)
*
|
2007-12-19 |
2019-09-24 |
Amgen Inc |
composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
|
|
ATE531372T1
(de)
*
|
2008-04-07 |
2011-11-15 |
Amgen Inc |
Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
|
|
CN102231984A
(zh)
*
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
|
|
AU2009310352A1
(en)
*
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
|
PA8852901A1
(es)
*
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
BRPI1008709B8
(pt)
|
2009-04-03 |
2021-05-25 |
Hoffmann La Roche |
dispersão sólida, formulação, composição e comprimido compreendendo {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridina-3-carbonil]-2,4-diflúor-fenil}-amida do ácido propano-1-sulfônico
|
|
EP3025724B1
(de)
|
2009-05-13 |
2018-07-11 |
The University of North Carolina At Chapel Hill |
Cyclinabhängige kinasehemmer und verfahren zur verwendung
|
|
US20110112127A1
(en)
|
2009-11-06 |
2011-05-12 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
PH12012501361A1
(en)
|
2009-12-31 |
2012-10-22 |
Centro Nac De Investigaciones Oncologicas Cnio |
Tricyclic compounds for use as kinase inhibitors
|
|
TWI619713B
(zh)
|
2010-04-21 |
2018-04-01 |
普雷辛肯公司 |
用於激酶調節的化合物和方法及其適應症
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
|
MY162950A
(en)
|
2011-02-07 |
2017-07-31 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
MX2013010871A
(es)
|
2011-03-23 |
2014-01-31 |
Amgen Inc |
Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
|
|
CN103534867B
(zh)
|
2011-06-17 |
2017-04-12 |
流体公司 |
含有磺酸根离子的离子液体
|
|
CA2868966C
(en)
|
2012-03-29 |
2021-01-26 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
TR201816077T4
(tr)
*
|
2013-02-21 |
2018-11-21 |
Pfizer |
Seçici bir cdk4/6 inhibitörünün katı formları.
|
|
MX2015012741A
(es)
*
|
2013-03-15 |
2016-02-19 |
Concert Pharmaceuticals Inc |
Palbociclib deuterado.
|
|
WO2014144740A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
WO2014144326A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient protection of normal cells during chemotherapy
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
WO2015161283A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
US9828373B2
(en)
*
|
2014-07-26 |
2017-11-28 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
|
|
WO2016016769A1
(en)
*
|
2014-07-31 |
2016-02-04 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
|
EP3180007A1
(de)
*
|
2014-08-14 |
2017-06-21 |
Sun Pharmaceutical Industries Ltd |
Kristalline formen von palbociclib
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
|
CN105616419A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
|
|
CN105616418A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
|
ES2941897T3
(es)
|
2014-11-12 |
2023-05-26 |
Seagen Inc |
Compuestos que interaccionan con glicanos y procedimientos de uso
|
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
|
CN105732615B
(zh)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk激酶抑制剂
|
|
DK3255046T3
(da)
|
2015-02-03 |
2020-01-20 |
Jiangsu Hengrui Medicine Co |
Hydroxyethylsulfonat af cyclin-afhængig proteinkinasehæmmer, krystallinsk form deraf og fremgangsmåde til fremstilling deraf
|
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
|
EP3078663A1
(de)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modifizierte partikel von palbociclib
|
|
CN104910149A
(zh)
*
|
2015-04-28 |
2015-09-16 |
上海百奇医药科技有限公司 |
一种Palbociclib制备方法
|
|
CN106117199A
(zh)
*
|
2015-05-04 |
2016-11-16 |
江苏恒瑞医药股份有限公司 |
一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
|
|
PT3305785T
(pt)
*
|
2015-05-29 |
2021-10-13 |
Teijin Pharma Ltd |
Derivado de pirido[3,4-d]pirimidina e seu sal farmaceuticamente aceitável
|
|
CR20170540A
(es)
*
|
2015-06-04 |
2018-02-02 |
Pfizer |
Formas de dosificación solidas de palbociclib
|
|
CN106317053A
(zh)
*
|
2015-06-29 |
2017-01-11 |
北大方正集团有限公司 |
一种帕博昔布晶型a的制备方法
|
|
ES2741958T3
(es)
|
2015-08-05 |
2020-02-12 |
Ratiopharm Gmbh |
Nueva forma cristalina y aductos de ácido acético de palbociclib
|
|
CN105085517B
(zh)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
|
CN106474129A
(zh)
*
|
2015-09-01 |
2017-03-08 |
上海方楠生物科技有限公司 |
一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
|
|
HU230962B1
(hu)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Palbociclib sók
|
|
SG11201803213XA
(en)
|
2015-11-12 |
2018-05-30 |
Siamab Therapeutics Inc |
Glycan-interacting compounds and methods of use
|
|
CN105418603A
(zh)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
一种高纯度帕布昔利布及其反应中间体的制备方法
|
|
CN106800553A
(zh)
*
|
2015-11-26 |
2017-06-06 |
上海科胜药物研发有限公司 |
一种帕博西尼二羟乙基磺酸盐的晶型
|
|
CN106800554A
(zh)
*
|
2015-11-26 |
2017-06-06 |
上海科胜药物研发有限公司 |
一种帕博西尼二盐酸盐的晶型及其制备方法
|
|
CN105541832A
(zh)
*
|
2015-12-15 |
2016-05-04 |
南京艾德凯腾生物医药有限责任公司 |
一种羟乙基磺酸盐帕布昔利布的制备方法
|
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
|
CN107137409A
(zh)
*
|
2016-03-01 |
2017-09-08 |
江苏恒瑞医药股份有限公司 |
一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
|
|
CN107137408A
(zh)
*
|
2016-03-01 |
2017-09-08 |
江苏恒瑞医药股份有限公司 |
一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
|
|
WO2017172734A1
(en)
*
|
2016-03-29 |
2017-10-05 |
Mayo Foundation For Medical Education And Research |
Treating cancer metastasis
|
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
|
WO2018001270A1
(en)
*
|
2016-06-30 |
2018-01-04 |
Noratech Pharmaceuticals, Inc. |
Palbociclib prodrugs and composition thereof
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
EP3481825A1
(de)
|
2016-07-07 |
2019-05-15 |
Plantex Ltd. |
Feste formen von palbociclibdimesylat
|
|
MY198534A
(en)
|
2016-08-15 |
2023-09-04 |
Pfizer |
Pyridopyrimdinone cdk2/4/6 inhibitors
|
|
WO2018065999A1
(en)
|
2016-10-07 |
2018-04-12 |
Mylan Laboratories Limited |
Novel polymorph of an intermediate for palbociclib synthesis
|
|
MX2019004602A
(es)
|
2016-10-20 |
2019-06-17 |
Pfizer |
Agentes anti-proliferativos para tratar pah.
|
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
|
US20190275049A1
(en)
|
2016-11-16 |
2019-09-12 |
Pfizer Inc. |
Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
|
|
EP3541847A4
(de)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
|
CN109996800B
(zh)
*
|
2016-11-28 |
2021-11-19 |
帝人制药株式会社 |
吡啶并[3,4-d]嘧啶衍生物或其溶剂合物的晶体
|
|
MX2019008158A
(es)
|
2017-01-06 |
2019-12-09 |
G1 Therapeutics Inc |
Terapia de combinacion para el tratamiento del cancer.
|
|
MX2019010202A
(es)
|
2017-03-03 |
2019-10-02 |
Seattle Genetics Inc |
Compuestos que interactuan con glicano y metodos de uso.
|
|
WO2018191950A1
(en)
*
|
2017-04-21 |
2018-10-25 |
Alnova Pharmaceuticals, Ltd. |
Palbociclib compositions and methods thereof
|
|
MX392531B
(es)
|
2017-06-29 |
2025-03-24 |
G1 Therapeutics Inc |
Formas morficas de g1t38 y metodos de preparacion de las mismas.
|
|
US11529353B2
(en)
|
2017-07-28 |
2022-12-20 |
Synthon B.V. |
Pharmaceutical composition comprising Palbociclib
|
|
TW201940166A
(zh)
*
|
2018-01-29 |
2019-10-16 |
美商貝達醫藥公司 |
作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途
|
|
KR102765922B1
(ko)
|
2018-02-06 |
2025-02-11 |
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 |
선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
|
|
JP2021514975A
(ja)
|
2018-02-27 |
2021-06-17 |
ファイザー・インク |
サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
|
|
PL3793609T3
(pl)
|
2018-05-14 |
2024-05-13 |
Pfizer Inc. |
Preparat w postaci doustnego roztworu
|
|
BR112021001233A2
(pt)
|
2018-07-23 |
2021-04-20 |
F. Hoffmann-La Roche Ag |
método para tratar câncer em um paciente, uso de uma quantidade terapeuticamente eficaz de gdc-0077 e quantidade terapeuticamente eficaz de gdc-0077
|
|
CN112839657B
(zh)
|
2018-08-24 |
2025-07-25 |
法码科思莫斯控股有限公司 |
1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
|
|
JP6952747B2
(ja)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
|
|
WO2020076432A1
(en)
|
2018-10-08 |
2020-04-16 |
Genentech, Inc. |
Methods of treating cancer with pi3k alpha inhibitors and metformin
|
|
US11424484B2
(en)
|
2019-01-24 |
2022-08-23 |
Octet Scientific, Inc. |
Zinc battery electrolyte additive
|
|
WO2020157709A1
(en)
|
2019-02-01 |
2020-08-06 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
|
US20220241412A1
(en)
|
2019-05-24 |
2022-08-04 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
CA3141452A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
CN110143948B
(zh)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
Cdk4/6抑制剂、其药物组合物、制备方法及应用
|
|
MX2022002415A
(es)
|
2019-08-26 |
2022-03-22 |
Arvinas Operations Inc |
Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
|
|
WO2021113219A1
(en)
|
2019-12-03 |
2021-06-10 |
Genentech, Inc. |
Combination therapies for treatment of breast cancer
|
|
US12539304B2
(en)
|
2020-03-05 |
2026-02-03 |
Pfizer Inc. |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
EP4667055A2
(de)
|
2020-07-15 |
2025-12-24 |
Pfizer Inc. |
Kat6-inhibitorverfahren und kombinationen zur krebsbehandlung
|
|
EP4181919A1
(de)
|
2020-07-20 |
2023-05-24 |
Pfizer Inc. |
Kombinationstherapie
|
|
WO2022063119A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
南京济群医药科技股份有限公司 |
一种羟乙磺酸哌柏西利的组合物及药物
|
|
CN114306245A
(zh)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
无定形固体分散体的药物组合物及其制备方法
|
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
|
CN113845520A
(zh)
*
|
2021-09-09 |
2021-12-28 |
安徽皓元药业有限公司 |
一种帕布昔利布乳清酸盐及其制备方法
|
|
IL313422A
(en)
|
2021-12-10 |
2024-08-01 |
Lilly Co Eli |
CDK4 and 6 inhibitor in combination with FULVESTRANT for the treatment of advanced or metastatic breast cancer in patients with advanced or metastatic breast cancer before CDK 4 and 4
|
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
|
CN114195784A
(zh)
*
|
2021-12-29 |
2022-03-18 |
斯坦德标准技术研究(湖北)有限公司 |
帕博西尼有关物质及其制备方法和应用
|
|
EP4302832A1
(de)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib-formulierung, die glucono-delta-lacton enthält
|
|
EP4302755B1
(de)
|
2022-07-07 |
2025-08-20 |
Lotus Pharmaceutical Co., Ltd. |
Eine aminosäure enthaltende palbociclib-formulierung
|
|
CN119604288A
(zh)
|
2022-07-29 |
2025-03-11 |
辉瑞大药厂 |
用于治疗癌症的包含kat6抑制剂的给药方案
|
|
TW202539669A
(zh)
|
2022-08-31 |
2025-10-16 |
美商亞文納營運公司 |
雌激素受體降解劑之給藥方案
|
|
CN120456897A
(zh)
|
2022-11-02 |
2025-08-08 |
佩特拉制药公司 |
用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
|
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024201340A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
|
|
WO2024201334A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
|
|
TW202532065A
(zh)
|
2023-12-04 |
2025-08-16 |
美商建南德克公司 |
治療乳癌之組合療法
|
|
WO2025202854A1
(en)
|
2024-03-27 |
2025-10-02 |
Pfizer Inc. |
Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
|
|
WO2026025013A2
(en)
|
2024-07-26 |
2026-01-29 |
Pfizer Inc. |
Combination therapy using cdk4 inhibitors for cancer treatments
|